Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ACCESS Consortium Expands Focus To ATMPs And ‘Urgently Needed’ Medicines

Executive Summary

A work-sharing group made up of regulators in Australia, Canada, Singapore, Switzerland and the UK has been expanded to include advanced therapy medicinal products, which could lead to greater harmonization in the regulatory approaches taken by different agencies.

You may also be interested in...



UK To Combat Clinical Trial Issues With Upstream Support For Sponsors & International Collaboration

The UK medicines regulator is mulling the possibility of drawing on its existing international regulatory partnerships, such as the ACCESS Consortium, to tackle challenges in its clinical trials sector, and says sponsors can expect greater support early in the trial process.

How The ACCESS Consortium’s New ‘Promise Pathway’ Can Benefit Drugmakers

Pharmaceutical companies that develop new medicines for life-threatening or severely debilitating conditions could be eligible to file for a priority review in the five ACCESS Consortium member countries under a new pilot scheme.

International Regulators Say Collaboration Is Key To Tackling Pharma Globalization Challenges

Regulators from Canada, the UK and Australia discuss their experiences of working together under both the ACCESS Consortium, an international regulatory worksharing coalition, and Project Orbis, a parallel review process designed to speed up access to oncology medicines.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS149416

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel